Drug intelligence / Profile preview

DA-5221

Development stage: Phase 3
Lead developer: Dong-A ST
Modality: Small Molecules
Administration: Oral

Overview

DA-5221 is an investigational small molecule drug developed by Dong-A ST for the treatment of type 2 diabetes mellitus. It acts as a sodium-glucose co-transporter 2 (SGLT2) inhibitor, a class of drugs that lowers blood glucose levels by preventing glucose reabsorption in the kidneys and promoting its excretion in urine. Clinical trials are ongoing to evaluate its efficacy and safety, including as part of combination therapy with other antidiabetic agents such as DPP-4 inhibitors[1][5][7]. The drug is currently in Phase 3 clinical development.

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on DA-5221.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-5221.

Explore the full profile